期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CMX001抗单纯疱疹病毒初步药效学研究 被引量：2

Effect of CMX001 against herpes simplex virus
原文传递
导出
摘要 目的观察西多福韦磷脂衍生物CMX001在体内外实验模型中的抗疱疹病毒药效。方法利用中性红染色法测定CMX001在Vero细胞培养条件下对单纯疱疹病毒(HSV)-1和HSV-2的抗病毒作用;在BALB/c小鼠阴道疱疹病毒感染模型中观察ACV乳膏和CMX001凝胶制剂在体内对HSV-2感染的治疗效果。结果 CMX001在Vero细胞上对HSV-1和HSV-2的半数抑制浓度(IC50)的平均值分别为0.073和0.070μmol/L;在体内实验当中,CMX001凝胶制剂对小鼠阴道HSV-2感染疗效较好,优于阳性对照组(阿昔洛韦乳膏)。结论 CMX001在体内外均对HSV有较强的抑制作用。 Objective To detect the anti-herpesvirus effect of CMX001 in the model of in vivo and in vitro experiments.Methods The antiviral effects of CMX001 on herpes simplex virus（ HSV）-1 and HSV-2 in Vero cells were measured by the neutral red uptake assay. The effect of ACV cream and CMX001 gel on the treatment of HSV-2 infection was observed in the model of vaginal herpesvirus infection in BALB / c mice. Results The median inhibitory concentration（ IC50） of CMX001 to HSV-1 and HSV-2 was 0. 073 and 0. 070 μmol / L,respectively. In the in vivo test,CMX001 gel preparation was more effective for the treatment of HSV-2 in the mouse vagina than the positive control group（ ACV cream）. Conclusion CMX001 has a strong inhibitory effect on herpes simplex virus in vivo and in vitro.
作者 付晓 贝祝春 孙雅洁 张东娜 徐力昆 赵冰 郭永建 宋亚彬 窦媛媛 王红 王洪权
机构地区 军事医学科学院微生物流行病研究所
出处 《军事医学》 CAS CSCD 北大核心 2016年第5期412-416,共5页 Military Medical Sciences
关键词 CMX001 凝胶剂 药效学 CMX001 gel preparation pharmacodynamics
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献21

  • 1李凡,刘晶星.医学微生物学[M].北京:人民卫生出版社,2008:186.
  • 2Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1 : a global review [ J ]. J Infect Dis,2002,186 ( Suppl 1 ) : S3 - S28.
  • 3Frobert E, Burrel S, Ducastelle-Lepretre S, et al. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France[ J ]. Antiviral Res,2014,111:36 - 41.
  • 4Castelo-Soccio L, Bemardin R, Stem J, et al. Successful treat- ment of acyclovir-resistant herpes simplex virus with intralesional eidofovir[ J]. Arch Dermatol,2010,146(2) :124 - 126.
  • 5Florescu DF, Keck MA. Development of CMX001 ( Brincidofo- vir) for the treatment of serious diseases or conditions caused by dsDNA viruses [ J]. Expert Rev Anti Infect Ther, 2014, 12 (10) :1171 - 1178.
  • 6Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies [ J]. J Infect Dis,2010,202(10) : 1492 - 1499.
  • 7Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates : activity against adeno- virus replication in vitro[J]. J Infect Dis, 2005,191,396 -399.
  • 8Aldern KA, Ciesla SL, Winegarden KL, et al. Increased antiviral activity of 1-O-hexadecycloxypropyl-[ 2-( 14 ) C ] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism [ J ]. Mol Pharmacol, 2003,63 ( 3 ) : 678 -681.
  • 9Magee WC, Aldern KA, Hostetler KY, et al. Cidofovir and ( S ) -9-[ 3-hydroxy-( 2-phosphonomethoxy ) propyl ] adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand [ J ]. Antimicrob Agents Chemother,2008,52 (2) :586 - 597.
  • 10Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections [ J ]. Viruses, 2010,2 ( 12 ) : 2740 - 2762.

二级参考文献31

  • 1Ghosal K, Ranjan A, Bhovmiik BB. A novel vaginal drug deliverysystem: anti-HIV bioadhesive film containing abacavir [ J]. J MaterSci Mater Med, 2014,25(7) ; 1679-1689.
  • 2de Aradjo Pereira RR, Bruschi ML. Vaginal mucoadhesive drug de-livery systems [J]. Drug Dev Jnd Pharm, 2012,38 (6) : 643-652.
  • 3Date AA,Shibata A,Goede M, et aL Development and evaluation ofa thermosensitive vaginal gel containing raltegravir + efavirenz loadednanoparticles for HIV prophylaxis [ J]. Antiviral Res, 2012, 96 (3):430436.
  • 4Machado RM, Paimeira-De-Oliveira A, Martinez-De-Oliveira J, etal. Vaginal films for drug delivery [ J]. Journal of PharmaceuticalSciences, 2013, 102 (7) : 2069-2081.
  • 5Kawarkhe S, Poddar SS. Designing of the mucoadhesive intravaginalspermicidal 51ms [ J] . Indian J Pharm Sci,2010,72 (5) :652-655.
  • 6Akil A,Parniak MA, Dezzuitti CS, et al. Development and Character-ization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Re-verse Transcriptase Inhibitor (NNRTI),for prevention of HIV-1 sexualtransmission [J]. Drug Deliv Transl Res, 2011,1 (3) :209-222.
  • 7Nakayama A, Yamaguchi N, Ohno Y, et al. Sustained-Release Pro-gesterone Vaginal Suppositories 3-Development and Clinical Feasibili-ty Testing- [ J]. Yakugaku Zasshi’ 2013,133 (6) ;727-736.
  • 8Baloglu E,Ay Senyigit Z,Karavana SY,et al. In vitro evaluation ofmucoadhesive vaginal tablets of antifungal drugs prepared with thiolat-ed polymer and development of a new dissolution technique for vaginalformulations [ J]. Chem Pharm Bull(Tokyo),2011,59 (8) :952-958.
  • 9Wang L, Tang X. A novel ketoconazole bioadhesive effervescent tab-let for va^nal delivery: design,in vitro and ' in vivo ' evaluation[ J].IntJ Pharm, 2008,350(1-2):181-187.
  • 10Thurman AR,Clark MR,Hurlburt JA,et al. Intravaginal rings asdelivery systems for microbicides and multipurpose prevention technol-ogies [J]. Int J Womens Health, 2013,5:695-708.

共引文献54

同被引文献15

引证文献2

二级引证文献2

军事医学
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部